-
EP3902813
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3902813
| EP3902813 - TARGETED DELIVERY OF THERAPEUTIC MOLECULES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 24.03.2023 Database last updated on 19.10.2024 | |
| Former | Request for examination was made Status updated on 01.10.2021 | ||
| Former | The international publication has been made Status updated on 04.07.2020 | Most recent event Tooltip | 24.03.2023 | Application deemed to be withdrawn | published on 26.04.2023 [2023/17] | Applicant(s) | For all designated states Sirnaomics, Inc. 401 Professional Drive Suite 280 Gaithersburg, MD 20879 / US | For all designated states Zhang, Peter No. 199 Dong Ping St. Suzhou Industry Park Suzhou 215125 / CN | [2021/44] | Inventor(s) | 01 /
ZHANG, Peter No. 199 Dong Ping St. Suzhou Industry Park Suzhou 215125 / CN | 02 /
LU, Xiaoyong 401 Professional Dr. Suite 280 Gaithersburg MD 20879 / US | 03 /
EVANS, David, M. 401 Professional Dr. Suite 280 Gaithersburg MD 20879 / US | 04 /
LU, Patrick, Y. 401 Professional Dr. Suite 280 Gaithersburg MD 20879 / US | 05 /
LU, Alan 401 Professional Dr. Suite 280 Gaithersburg MD 20879 / US | 06 /
XU, John 401 Professional Dr. Suite 280 Gaithersburg MD 20879 / US | [N/P] |
| Former [2021/44] | 01 /
LU, Xiaoyong Gaithersburg, MD 20879 / US | ||
| 02 /
EVANS, David, M. Gaithersburg, MD 20879 / US | |||
| 03 /
LU, Patrick, Y. Gaithersburg, MD 20879 / US | |||
| 04 /
LU, Alan Gaithersburg, MD 20879 / US | |||
| 05 /
XU, John Gaithersburg, MD 20879 / US | |||
| 06 /
ZHANG, Peter Suzhou 215125 / CN | Representative(s) | Danner, Stefan Danner BioPharm IP Ludwigstraße 8 80539 München / DE | [2021/44] | Application number, filing date | 19903962.9 | 22.12.2019 | [2021/44] | WO2019US68205 | Priority number, date | US201862786213P | 28.12.2018 Original published format: US 201862786213 P | [2021/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2020139788 | Date: | 02.07.2020 | Language: | EN | [2020/27] | Type: | A2 Application without search report | No.: | EP3902813 | Date: | 03.11.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 02.07.2020 takes the place of the publication of the European patent application. | [2021/44] | Search report(s) | International search report - published on: | US | 06.08.2020 | (Supplementary) European search report - dispatched on: | EP | 04.04.2022 | Classification | IPC: | C07H15/26, C12N15/113, A61K31/7088, A61P35/00 | [2022/18] | CPC: |
A61K47/549 (EP,KR);
A61K47/60 (KR,US);
A61K31/7105 (KR);
A61K31/7115 (US);
A61K31/713 (KR);
A61K47/10 (KR);
A61K47/34 (KR);
A61K48/00 (KR);
A61P35/00 (KR);
C12N15/113 (EP,KR,US);
A61K47/593 (KR);
C12N15/1136 (EP,KR);
C12N15/1137 (EP,KR);
C12N2310/14 (EP,KR);
C12N2310/321 (KR);
C12N2310/3521 (KR)
(-)
| C-Set: |
C12N2310/321, C12N2310/3521 (EP)
|
| Former IPC [2021/44] | C07H15/26, C12N15/113 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/44] | Title | German: | GEZIELTE ABGABE THERAPEUTISCHER MOLEKÜLE | [2021/44] | English: | TARGETED DELIVERY OF THERAPEUTIC MOLECULES | [2021/44] | French: | ADMINISTRATION CIBLÉE DE MOLÉCULES THÉRAPEUTIQUES | [2021/44] | Entry into regional phase | 23.07.2021 | National basic fee paid | 23.07.2021 | Search fee paid | 23.07.2021 | Designation fee(s) paid | 23.07.2021 | Examination fee paid | Examination procedure | 23.07.2021 | Amendment by applicant (claims and/or description) | 23.07.2021 | Examination requested [2021/44] | 08.11.2022 | Application deemed to be withdrawn, date of legal effect [2023/17] | 01.12.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2023/17] | Fees paid | Renewal fee | 17.12.2021 | Renewal fee patent year 03 | 14.11.2022 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO2010039548 (ALNYLAM PHARMACEUTICALS INC [US], et al); | [X]WO2012092373 (ARROWHEAD RES CORP [US], et al); | [X]WO2015069932 (SOLSTICE BIOLOG LTD [IE], et al); | [Y]WO2016055601 (HOFFMANN LA ROCHE [CH], et al); | [X]WO2016100401 (DICERNA PHARMACEUTICALS INC [US]); | [X]WO2017083368 (PFIZER [US], et al); | [Y]WO2018004004 (KYOWA HAKKO KIRIN CO LTD [JP]); | [X]WO2018132432 (ARROWHEAD PHARMACEUTICALS INC [US]); | [YP]EP3498724 (KYOWA HAKKO KIRIN CO LTD [JP]); | International search | [A]US2008146782 (DEFREES SHAWN [US], et al); | [A]US2011124853 (CHEN TONGQIAN [US], et al); | [Y]US2013137644 (ALLUIS BERTRAND [FR], et al); | [Y]US2018079769 (TELLERS DAVID [US], et al) |